Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 23315324.
- Also identified by DOI 10.1093/infdis/jit017.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
HIV-1 drug resistance represents a major obstacle to infection and disease control. This retrospective study analyzes trends and determinants of resistance in antiretroviral treatment (ART)-exposed individuals across 7 countries in Europe. Of 20 323 cases, 80% carried at least one resistance mutation: these declined from 81% in 1997 to 71% in 2008. Predicted extensive 3-class resistance was rare (3.2% considering the cumulative genotype) and peaked at 4.5% in 2005, decreasing thereafter. The proportion of cases exhausting available drug options dropped from 32% in 2000 to 1% in 2008. Reduced risk of resistance over calendar years was confirmed by multivariable analysis.
Medical subject headings
- Drug Resistance, Multiple, Viral
- HIV Infections
- HIV-1
- Reverse Transcriptase Inhibitors